Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 9, 2007

Bio-Bridge Science and Chinese Academy of Medical Sciences Tackle HPV

  • Bio-Bridge Science entered into a cooperative agreement with the Institute of Basic Medical Sciences at the Chinese Academy of Medical Sciences to research and develop a human papillomavirus polyvalent vaccine using prokaryotic expression system.

    This vaccine is designed to prevent infection by human papillomavirus types 6, 11, 16, 18, 31, 45, and 58. This is expected to provide broader protection than the current vaccine on the market and have much lower production costs, according to Bio-Bridge.

    Under the agreement, Bio-Bridge has been granted the preferential right to develop the vaccine and enjoys a 60% interest in the project.

    "We believe that our agreement with the Chinese Academy of Medical Sciences will enable us to solidify our research capability in China as we try to introduce more potential vaccine products in addition to our current vaccine pipeline,” explains Liang Qiao, chairman and CEO of Bio-Bridge.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »